Peyronie Disease
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
UNION therapeuticsDenmark - Hellerup
1 program1
Collagenase Clostridium HistolyticumPhase 41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
UNION therapeuticsCollagenase Clostridium Histolyticum
Dornier MedTechLow intensity choc waves therapy
Clinical Trials (2)
Total enrollment: 160 patients across 2 trials
Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease
Start: Oct 2024Est. completion: Oct 202940 patients
Phase 4Recruiting
Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease
Start: Apr 2021Est. completion: May 2024120 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 160 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.